Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2022-03-16 Regulatory Filings
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Non-Dilutive Grant Research Award
Regulatory Filings Classification · 100% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding boilerplate text stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a specific corporate event: receiving a non-dilutive research grant award. This type of immediate, material corporate news release, especially one originating from RNS, fits best under the general 'Regulatory Filings' category (RNS) as it is a broad announcement that doesn't specifically match the more specialized categories like ER, CAP, or DIV. Given the document length (5221 chars) and its nature as a direct announcement rather than a detailed report, RNS is the most appropriate classification.
2022-03-16 English
Notification of Major Holdings
Major Shareholding Notification Classification · 98% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' and the footer mentioning the London Stock Exchange and the Financial Conduct Authority (FCA). The content is a 'TR-1: Standard form for notification of major holdings,' which details changes in voting rights held by a shareholder (Adrian Beeston) crossing a threshold. This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is an RNS filing, MRQ is the more specific and accurate classification for a TR-1 form.
2022-01-18 English
First Day of Dealings
Share Issue/Capital Change Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding paragraph stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the commencement of share dealings (listing) on the London Stock Exchange following an oversubscribed placing to raise capital (£3.7 million). This is a significant corporate event announcement. While it relates to capital raising (CAP) and share structure (SHA), the primary nature of the filing itself, distributed via the RNS system, makes 'Regulatory Filings' (RNS) the most appropriate general classification for this type of immediate market disclosure, especially since it is not a comprehensive report like a 10-K or IR. Given the specific context of an LSE listing announcement distributed via RNS, RNS is the best fit as a general regulatory disclosure.
2022-01-17 English
GENFLOW BIOSCIENCES PLC - Single prospectus
Capital/Financing Update Classification · 100% confidence The document is explicitly titled as a 'prospectus' and contains sections standard to an IPO or capital raising document, such as 'Risk Factors', 'The Placing', 'Expected Timetable', and 'Historic Financial Information'. It is prepared in accordance with the Prospectus Regulation Rules of the Financial Conduct Authority (FCA) for the purpose of admitting shares to the London Stock Exchange. Since it details a new share issuance and capital raising activity, it falls under the category of Capital/Financing Update.
2022-01-11 English
Genflow Biosciences Intention to Float
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement dated January 10, 2022, from Genflow Biosciences Plc. The key content is the 'Intention to Float on the London Stock Exchange' and details about an oversubscribed placing, the intended listing segment (Standard Listing), and the use of IPO proceeds. This announcement is a formal notification to the market regarding a significant corporate action (IPO/listing) and capital raising, which is typically disseminated via regulatory news wires. Although it discusses future financial plans and includes management details, the primary purpose is the announcement of the intention to list and the associated fundraising, which fits best under a general regulatory announcement category. Since it is not the final prospectus, the full annual report (10-K), or a specific management/board change announcement, the most appropriate classification is Regulatory Filings (RNS), as it is a formal market disclosure disseminated through the RNS system.
2022-01-10 English
[change-account-reference-date-company-current-shortened] made_up_date=2022-01-31, new_date=2021-12-31
Regulatory Filings
2021-11-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.